Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...

Novo Nordisk stock took a big hit early Tuesday after the Danish weight-loss drugmaker unexpectedly cuts its full-year ...

About 2% of U.S. adults use GLP-1 drugs, but results vary. Diet, exercise, and mental health remain key to long-term success.

Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type ...

The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, and Mounjaro® has transformed obesity care and created an unexpected cosmetic challenge. Rapid fat loss can leave ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

The Ozempic makeover trend is sweeping the nation. Discover what it is, what experts warn, and why it’s more complicated than ...

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...